10 Things Investors Are Really Evaluating in Your Commercial Narrative

“The market is huge” is not a commercial strategy, and sophisticated investors know it. They’ve heard the line a thousand times, and it tells them nothing about whether the science has the potential to become a business. The ten things below are what they’re actually weighing while you present, and any one of them can be the reason a strong asset gets a pass or a weak term sheet.

1. A credible path to patients.

Investors don’t fund molecules in isolation. They fund a defensible path from asset to business. The data gets you the meeting; what they’re really listening for is whether you can trace the path from there: what the barriers are from diagnosis to treatment, and what has to be true for the patient to actually get the drug.

2. Whether you’ve thought about how the asset gets paid for.

Coverage, pricing, and access are where a lot of “huge markets” turn out to be a fraction of the big number.

Investors want to see that you know what it will take to get reimbursed, not just approved.

3. Which assumptions your case rests on.

A strong story calls out its own critical assumptions and the associated risks. When you can point to them before they do, you show that you know where the case is solid and where it’s exposed.

4. Whether you’ve stress-tested those assumptions.

Having a number isn’t enough. What builds confidence is evidence you’ve pressure tested it yourself and it held.

5. Why this asset will succeed, not just that it might.

“It could be big” is wishful thinking. “It wins for these specific reasons, against these specific alternatives” is a case. Investors can tell the difference in the first two minutes.

6. The quality of the thinking behind an uncertain answer.

Investors lose confidence not when the answer is uncertain, but when the thinking behind it is thin. “We don’t know yet, and here’s how we’re approaching it” establishes credibility. A big number with nothing behind it doesn’t.

7. What you could have controlled and didn’t.

The commercial narrative is the part you can build years in advance, long before anyone asks for it. You can’t rush the data, but you can build the story, so a thin one reads as a gap you failed to address.

8. Whether partners take you seriously.

A credible commercial case is what gets you to the partnering table, and lets you hold your ground once you’re there. Without it, you may not get the conversation at all.

9. The terms, not just the yes.

The commercial narrative rarely decides only whether you raise. It decides the valuation you raise at, and that difference compounds through every round after.

10. Whether you know what would change your mind.

The most reassuring thing a CEO can say is “here’s what would make us rethink this.” It shows the case is well thought out, not rehearsed.

The best commercial story isn’t the most optimistic one. It’s the most deliberately reasoned one, and it’s built long before you think you need it.